Charles Schwab’s Arcus Biosciences RCUS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$6.32M Buy
776,742
+62,740
+9% +$511K ﹤0.01% 2230
2025
Q1
$5.6M Buy
714,002
+134,379
+23% +$1.05M ﹤0.01% 2222
2024
Q4
$8.63M Buy
579,623
+12,644
+2% +$188K ﹤0.01% 2079
2024
Q3
$8.67M Buy
566,979
+59,536
+12% +$910K ﹤0.01% 2097
2024
Q2
$7.73M Buy
507,443
+14,167
+3% +$216K ﹤0.01% 2156
2024
Q1
$9.31M Buy
493,276
+21,094
+4% +$398K ﹤0.01% 2020
2023
Q4
$9.02M Buy
472,182
+11,341
+2% +$217K ﹤0.01% 2041
2023
Q3
$8.27M Buy
460,841
+24,100
+6% +$433K ﹤0.01% 2008
2023
Q2
$8.87M Buy
436,741
+15,050
+4% +$306K ﹤0.01% 1960
2023
Q1
$7.69M Buy
421,691
+32,971
+8% +$601K ﹤0.01% 1993
2022
Q4
$8.04M Buy
388,720
+9,626
+3% +$199K ﹤0.01% 1978
2022
Q3
$9.92M Buy
379,094
+35,813
+10% +$937K ﹤0.01% 1835
2022
Q2
$8.7M Buy
343,281
+12,630
+4% +$320K ﹤0.01% 1910
2022
Q1
$10.4M Buy
330,651
+8,501
+3% +$268K ﹤0.01% 1932
2021
Q4
$13M Sell
322,150
-33,091
-9% -$1.34M ﹤0.01% 1861
2021
Q3
$12.4M Buy
355,241
+10,682
+3% +$373K ﹤0.01% 1883
2021
Q2
$9.46M Buy
344,559
+11,288
+3% +$310K ﹤0.01% 2033
2021
Q1
$9.36M Buy
333,271
+46,191
+16% +$1.3M ﹤0.01% 1996
2020
Q4
$7.45M Buy
287,080
+4,107
+1% +$107K ﹤0.01% 2025
2020
Q3
$4.85M Buy
282,973
+26,720
+10% +$458K ﹤0.01% 2074
2020
Q2
$6.34M Buy
256,253
+60,012
+31% +$1.48M ﹤0.01% 1907
2020
Q1
$2.72M Buy
196,241
+4,478
+2% +$62.2K ﹤0.01% 2138
2019
Q4
$1.94M Buy
191,763
+2,078
+1% +$21K ﹤0.01% 2430
2019
Q3
$1.73M Buy
189,685
+92,558
+95% +$843K ﹤0.01% 2429
2019
Q2
$773K Sell
97,127
-1,609
-2% -$12.8K ﹤0.01% 2660
2019
Q1
$1.23M Buy
98,736
+4,897
+5% +$61.2K ﹤0.01% 2489
2018
Q4
$1.01M Buy
93,839
+43,092
+85% +$464K ﹤0.01% 2535
2018
Q3
$708K Buy
50,747
+10,706
+27% +$149K ﹤0.01% 2723
2018
Q2
$491K Buy
+40,041
New +$491K ﹤0.01% 2809